Deletions of chromosome 6q have been reported in several hematological malignancies, but data are not conclusive regarding their biological and prognostic impact. Therefore, we focused on pediatric patients diagnosed with T-cell lymphoblastic lymphoma (T-LBL) treated uniformly according to the NHL-BFM95 protocol. We used loss-of-heterozygosity (LOH) analysis of 25 microsatellite markers located on chromosome 6q14-q24. Fragment-length analysis was performed on ABI-PRISM3100 Genetic-Analyzer. Eligibility criterion was X3 informative markers. Between April 1995 and March 2003, 185 T-LBL patients were treated according to the NHL-BFM95 protocol. Five-year event-free (EFS) and disease-free survival (DFS) were 7973 and 8773% (median follow-up 4.7 [1.2-10.1] years). Sixty-one patients were evaluable for LOH analysis, including 18 out of 23 patients with relapse. EFS and DFS were 6776 and 6976% for these 61 patients. Testing of 853 markers in the 61 patients identified the presence of LOH in 19 patients (31%): 13 of the 18 relapse patients and five of the 41 in complete remission (odds ratio 18.7, 95% confidence interval 4.7-75.3). One LOH-positive patient died from treatment-related toxicity. We conclude that LOH on chromosome 6q14-q24 may have conferred a high risk of relapse on our group of children with T-LBL treated according to the NHL-BFM95 protocol.
Introduction
Specific chromosomal aberrations in some hematological malignancies serve as diagnostic criteria or criteria for risk stratification.
1,2 However, until now, no genetic alteration with comparable impact has been identified in pediatric patients with T-cell lymphoblastic lymphoma (T-LBL), which might be attributed to the scarcity of adequate tumor tissue for cytogenetic analysis. Loss-of-heterozygosity (LOH) analysis is an alternative method to detect deletions of chromosomal material, which allows to analyze specimens that do not fulfill the prerequisites in terms of quantity and quality necessary for other methods, for example, fluorescence in situ hybridization or cytogenetics.
Deletions of chromosome 6q have been reported in a variety of hematological malignancies [3] [4] [5] [6] as well as in solid tumors, [7] [8] [9] suggesting the presence of a tumor suppressor gene on chromosome 6q. A number of studies on hematological malignancies narrowed down different minimal regions of deletion, [10] [11] [12] [13] [14] [15] [16] [17] and two studies identified candidate genes localized in the minimal deleted region of the study samples, but their tumor suppressor role has not yet been confirmed. 18, 19 Concerning the clinical value, some studies claim deletions of chromosome 6q to be of no prognostic impact, [20] [21] [22] [23] whereas other studies associate them with inferior treatment response. 3, 12, [24] [25] [26] [27] [28] [29] [30] Because of inconsistent findings, the clinical impact of chromosome 6 deletions remains unclear, and these deletions might have different effects in different biological entities. In addition, the prognostic value might depend on treatment. Therefore, we focused our retrospective study on 61 pediatric patients diagnosed with T-LBL and treated uniformly according to the NHL-BFM95 protocol. 31 We focused on the proximal part of chromosome 6q, because cytogenetic data from four relapsed index patients from trial NHL-BFM95 exhibited a common deleted region at chromosomal band 6q15-q16 (Table 1) . Here we present data on the frequency and prognostic impact of LOH on chromosome 6q14-q24 in a distinct and well-characterized cohort of pediatric T-LBL patients.
Patients
From April 1995 to March 2003, 185 patients up to 19 years old and diagnosed with T-LBL were treated according to protocol NHL-BFM95 in 76 centers in Austria, Germany and Switzerland after informed consent of the patients and/or their guardians. From this cohort, cases were chosen for the current analysis according to the following selection criteria: (1) treatment according to protocol NHL-BFM95, (2) T-cell immunophenotype of LBL, (3) availability of tumor DNA and germline control DNA and (4) three or more informative markers for each patient. Markers were regarded as informative when two different-sized fragments of the microsatellite marker were detected in germline DNA, and analysis of tumor DNA showed either a heterozygous pattern or LOH. Seventy-six patients fulfilled the first three steps of selection. In 15 patients, fewer than three informative markers were detected; for this reason, these 15 patients were not included in the analyses. Therefore a total of 61 patients fulfilled all four selection criteria. In the total cohort of 185 patients, 23 patients suffered from relapse. The evaluable group of 61 patients included 18 of the 23 relapsed patients. There was no further selection of samples besides the four selection criteria defined above. An explanation of the higher availability of specimens from the group of relapsed patients might be that at the time of relapse, the treating centers provided additional initial diagnostic tumor samples together with subsequent tumor samples for comparative analysis.
Diagnosis and therapy
The diagnosis was established by histopathology of the lymph node or tumor biopsy and/or by cytological 32 and immunophenotypic examination 33 of cells from malignant effusions (pleural effusion, ascites, pericardial effusion). Cases were classified according to the updated Kiel classification 34 and the WHO Classification of Haematological Malignancies. 35 Subclassification of immunophenotypic subgroups was performed according to EGIL criteria. 36 In more than 90% of cases, the diagnosis was centrally reviewed by one of the reference laboratories (AR, RP and/or WL). Staging was performed according to the St Jude staging system. 37 Patients were treated according to the NHL-BFM95 protocol for lymphoblastic lymphoma as described earlier. 31 
LOH analysis
High-molecular-weight germline DNA was extracted from blood (PB) and bone marrow (BM) smears, or from frozen peripheral blood and BM cells using the EZNA Blood DNA kit (PEQLAB, Erlangen, Germany) according to the manufacturer's recommendations. In all 61 patients, no infiltration by lymphoma cells in the PB and BM was demonstrated by morphological analyses (central review, AR, BB); additionally, in half of the cases, no infiltration by lymphoma cells in the PB and BM was demonstrated by flow cytometry analysis (WL). Initial tumor DNA from the time of diagnosis was isolated from tumor touch imprints, cytospin preparations of malignant effusions or frozen tumor cells using the peqGOLD Forensic DNA kit (PEQLAB, Erlangen, Germany). Patients whose material was available only from the relapse and not from the initial diagnosis were not included in this analysis.
Patient samples were analyzed with a set of 25 microsatellite markers spanning a 64-Mb region on chromosome 6q14-q24. Markers were chosen based on two criteria: the first selection criterion was that they had to cover bands 6q15-q16, which represented the common minimal deleted region in cytogenetic analysis of four relapsed LBL patients in the NHL-BFM95 trial (Table 1) , and they should cover the minimal deleted regions of reported deletions of proximal 6q in hematological malignancies. [16] [17] [18] 23, [38] [39] [40] The second selection criterion was a preferred rate of 475% heterozygosity, as reported in the Genome Database (GDB http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db ¼ Genome). The following microsatellite markers were analyzed: D6S1589, D6S2407, D6S1609, D6S1627, D6S1004, D6S1644, D6S1043, D6S1274, D6S300, D6S1682, D6S1284, D6S1716, D6S1717, D6S468, D6S283, D6S1580, D6S1021, D6S447, D6S278, D6S1647, D6S261, D6S1657, D6S1639, D6S435 and D6S310. Primer sequences for amplifying the repeats were retrieved from GDB and the ensembl data base (www.ensembl.org), and PCR primers were synthesized by MWG Biotech (Ebersberg, Germany) with the forward primer labeled at the 5 0 end with fluorescent dye 6-FAM. Paired normal and tumor DNA samples from each patient were amplified with PE AmpliTaq Gold enzyme (Applied Biosystems, Branchburg, NJ, USA) in PCR reactions using 5-80 ng of genomic DNA as a template. PCR was performed in a 25-ml reaction volume containing 0.4 ml of 50mM primer solution and 2.5 ml 10 Â standard PCR buffer. Thirty-five cycles were carried out in a thermal cycler (Perkin-Elmer, Foster City, CA, USA and Biometra, Goettingen, Germany) under conditions specified by GDB. Then, 1.5-ml aliquots of the PCR products were mixed with 18.5 ml HiDi-formamide and 0.5 ml size standard, denatured and subjected to electrophoresis on a genetic analyzer Of index patients I and II, no samples were available for LOH analyses. Index patients III and IV were analyzed for LOH (cases 2 and 3).
Impact of LOH at chromosome 6q in T-cell lymphoblastic lymphoma B Burkhardt et al (ABI PRISM 3100 Genetic Analyzer, Foster City, CA, USA). The automatically collected data from fragment-length analysis were analyzed with GeneScan software as described in the manufacturer's manual. To define LOH, ratios for the height of peak levels of the two alleles in tumor material and in germline DNA were compared. A tumor material ratio below 50% or above 150% of the germline DNA ratio was considered indicative of LOH. Homozygous pattern of the germline control and microsatellite instability rendered the microsatellite marker not evaluable for LOH analysis in this patient. A microsatellite marker was considered unstable if the PCR product of its tumor DNA had altered fragment lengths compared to alleles in the corresponding germline DNA. 41 The most centromeric and telomeric markers with LOH defined the putative deleted region. LOH findings were retested and confirmed in a second experiment in 78% of cases. All 25 microsatellite markers were retested in a second experiment with newly isolated tumor DNA in 16 patients (cases 1, 3, 11, 14, 15, 17, 18, 19, 26, 27, 35, 40, 43, 50, 51 and 54) .
Statistical analysis
Event-free survival (EFS) and disease-free survival (DFS) were calculated according to Kaplan and Meier 42 with differences compared by the log-rank test. 43 EFS was calculated from the date of diagnosis to the first event (death from any cause, relapse or second malignancy) or to the date of the last follow-up. DFS was calculated from the date of diagnosis to relapse. Patients lost to follow-up were censored at the time of their last followup examination. Differences in the distribution of individual parameters among patient subsets were analyzed using the w 2 test or Fisher's exact test. Odds ratios were calculated and tested using standard methods. 44 For the group of 185 T-LBL patients, corrected estimates for the probabilities of relapse in patients with and without LOH and the resulting risk ratio (RR) were calculated according to Bayes' formula. The estimates of the corrected probabilities and the RR were based on the relapse rate of 23/179 for the total group of patients, who were treated according to the protocol and who did not die from early complications or treatment-related toxicity (N ¼ 6; Table 2 ). The statistical analysis was carried out using the SAS statistical program (SAS-PC, Version 9.1, Cary, NC, USA: SAS Institute Inc.). Follow-up data were updated as of August 2005.
Results
pEFS and pDFS at 5 years were 7973 and 8773% for the total cohort of 185 T-LBL patients with a total of 23 patients who suffered from relapse (median follow-up of 4.7 (1.2-10.1) years). On the basis of criteria described above, 61 of 185 patients were evaluable for analysis (Table 1 ). In line with the NHL-BFM95 protocol, three of the 61 analyzed patients received intensified therapy with six high-risk courses of the ALL-BFM protocol 45 because of less than 70% tumor reduction after 5 weeks. pEFS and pDFS were 6776 and 6976% for the 61 evaluable patients including 18 of the 23 relapsed patients.
Fragment-length analysis of germline DNA and tumor DNA of the 61 patients was successful for a total of 853 markers with LOH of 73 markers, retention of the heterozygous status in 481 markers, homozygous pattern in 222 markers and microsatellite instability in 77 markers. Four patients were included with three informative markers, eight patients with four or five informative markers, 25 patients with six to nine informative markers and 24 patients with 10 or more informative markers. In the group of 43 patients without relapse, 39 patients had four or more informative markers.
LOH of one or more markers was detected in 19 patients (31%). The informative results and the putative deleted regions of these 19 patients are shown in Figure 1 . Four cases showed LOH of all informative markers (cases 1, 2, 3 and 4). In 15 cases, interstitial deletions of chromosome 6q were detected. Two cases showed two regions of deletion (cases 5 and 17). The following five markers were most frequently involved in the putative deleted regions of the 19 cases with LOH: D6S1284, D6S1716, D6S1717, D6D468 and D6S1580. All five markers were localized at chromosomal band 6q16, which thus represents the chromosomal region most frequently identified as deleted in this analysis. Patients who died from initial complications and treatment-related toxicity were excluded from further analyses of the prognostic impact of LOH at chromosome 6q14-q24.
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Impact of chromosome 6q14-q24 LOH on outcome
The clinical features of the 19 LOH-positive patients were not significantly different from those of the 42 patients with no detectable LOH with respect to sex ratio, age, stage of disease, BM involvement, mediastinal involvement and central nervous system (CNS) involvement. The only exception was the subclassification of the immunophenotype, which differed significantly between the two groups (Table 3) . Of the 61 patients, two cases (cases 58 and 19) could not be included in outcome assessments because of death from treatment-related toxicity or initial complications; thus, 18 evaluable patients with LOH and 41 evaluable patients without LOH were included in the outcome analysis. LOH was detected in 13 of the 18 analyzed patients with relapse compared to five out of the 41 patients who stayed in continuous complete remission (odds ratio 18.7, 95% confidence interval 5.7-75.3). Because of the overrepresentation of relapse patients in the analyzed group of 59 patients, this group was not representative of the total group of 179 T-LBL patients with sufficient follow-up. Using Bayes' formula, this selection bias for relapse patients was corrected for the estimation of the probability of relapse in patients with and without LOH and the resulting RR. Given the relapse rate of 23/179 for the total cohort of T-LBL patients, the corrected probability of relapse in patients with no detectable LOH was 4.5%, whereas the probability of relapse in patients with detectable LOH was 46.6%. The corrected RR for relapse in patients with LOH was 10.5.
Critical region of deletion
The rate of LOH was defined as the number of findings of LOH in all informative results per marker. To determine the prognostic impact of LOH at the different markers, the rate of LOH was analyzed separately for patients in remission and for relapsed patients. As shown in Table 4 , the rate of LOH was significantly different between the two groups for the following seven markers: D6S1589, D6S2407, D6S1627, D6S1284, D6S1716, D6S468 and D6S310. The difference in the LOH rate was most significant for marker D6S1284, which was deleted in six out of nine informative relapse patients but none of the 17 informative patients in remission.
Because the physical distance between markers D6S1284 and D6S1716 is less than 30 kb, they were considered as representing the same chromosomal locus. Figure 1 shows the putative deleted region in patients with and without relapse. In nine of the 13 relapse patients with detectable LOH, the putative deleted region spanned markers D6S1284 and/or D6S1716 (cases 1, 3, 4, 2, 6, 7, 10, 13 and 8). In case 5, LOH analyses revealed a deletion of chromosomal band 6q15 and a second deleted region involving marker D6S310 on chromosomal band 6q24. Markers D6S1717 (6q16), D6S1021 (6q16) and D6S261 (6q21) were retained as heterozygous, whereas markers D6S1284 and D6S1716 were not informative. In case 11, marker D6S1284 showed heterozygous patterns, whereas marker D6S1716 was homozygous. In the remaining two cases with relapse (cases 9 and 12), marker D6S1284 was homozygous and marker D61716 did not provide an evaluable result. Therefore, the putative deleted region spanned markers D6S1284 and/or D6S1716 in nine of 18 analyzed relapsed patients compared with two of 41 patients in complete remission (cases 16 and 17) (Figure 1 ).
Correlation of cytogenetic findings and results of LOH analysis
Cytogenetic data from diagnostic tumor samples were available in 11 of the 61 evaluable patients (Table 1) . In six cases, neither cytogenetics nor LOH analysis revealed structural abnormalities in chromosome 6q (cases 26, 45, 34, 55, 43 and 54). In case 2, a cytogenetically described deletion del(6)(q1?2q1?6) was confirmed by LOH analysis; however, LOH was also detected for markers D6S278 and D6S310, which were allocated to Figure 1 Putative deleted region in patients with and without relapse. Case 19 with loss of heterozygosity of marker D6S1004 is not shown in this figure. The patient died 6 months after the start of treatment owing to treatment-related toxicity and therefore could not be allocated to one of the two groups.
Impact of LOH at chromosome 6q in T-cell lymphoblastic lymphoma B Burkhardt et al chromosomal bands 6q21 and 6q24. In case 11, cytogenetic analysis identified a balanced translocation involving chromosomal band 6q24. In this case, LOH was detected for marker D6S1580, meaning that a cytogenetically cryptic deletion occurred concomitantly to the translocation. A karyotype with aberrations not involving chromosome 6q was reported [47,XY, þ 8,i(9)(q10),t(10;11)(p13;q14)] in case 15. However, LOH analysis detected a very small deletion-involving marker D6S468 assigned to chromosome band 6q16. In two cases (cases 6 and 3), normal karyotypes were reported in diagnostic tumor samples. LOH analysis, however, detected deletions of chromosome 6q in both cases: in case 6, there was an interstitial deletion of markers assigned to bands 6q16-q21, and in case 3, LOH was identified for all informative markers. In this latter case, cytogenetic analysis at the time of relapse revealed a 6q deletion.
Discussion and conclusion
So far, neither the role in pathogenesis nor the impact on treatment outcome of patients had been clarified for the frequently reported chromosomal aberration del(6q). We focused our study on patients with T-LBL, a clearly defined biological entity, uniformly treated according to the NHL-BFM95 protocol. In the 61 patient samples, chromosomal region 6q14-q24 was examined by LOH analysis using a set of 25 microsatellite markers. LOH of at least one marker was detected in 19 of the 61 T-LBL patients (31%). Correlated with cytogenetic data, del(6q) was detected more frequently with LOH analysis than by standard karyotyping. This observation is in line with data obtained in pediatric ALL, a biologically closely related disease. In these patients, cytogenetic analysis revealed deletions of chromosome 6q in 8-18%, 20, 22, 46 whereas LOH analysis detected del(6q) in 32%. 39 The selection bias of evaluable patients in the current analysis necessitates caution about whether the 31% frequency of del(6q) is representative for childhood T-LBL. This question can be answered through further studies with completely unselected patient cohorts.
Concerning the prognostic impact of chromosome 6q deletions, we found that detectable LOH at chromosome 6q14-q24 was associated with poor outcome in pediatric T-LBL patients, with an odds ratio of almost 19. For the group of T-LBL patients of trial NHL-BFM95, the estimated probability of relapse in patients without detectable LOH at 6q14-q24 was below 5%; it was almost 10 times higher in patients with LOH. Because of the overrepresentation of relapsed patients in the group of 61 analyzed patients, lifetime analyses were not allowed, and an unbiased estimate for the relapse rate over time (probability of DFS) for LOH-positive and -negative patients is not possible. A prospective study is necessary to confirm estimated absolute risks for relapse and the corrected RR for relapse in LOHpositive and -negative patients. However, the odds ratio calculation, which is adequate for our selected case-control populations, confirmed a significant difference in the outcome between patients with and without LOH. Concerning clinical parameters, the analyzed group of 61 patients was representative of the 185 T-LBL patients except for more frequent CNS involvement and a greater percentage of female subjects among the 61 who were analyzed. CNS involvement has no prognostic impact, but adolescent girls had inferior outcome compared to other patients with T-LBL in earlier analyses. 47, 48 Comparison of the 19 LOH-positive patients with the 42 LOH-negative patients showed no greater frequency of female subjects or adolescents in the LOH-positive group, however.
Through detailed case-by-case analysis, we tried to narrow down the deletion region that might be critical for patient outcome. We analyzed the rate of LOH for each of the markers, comparing relapsed patients with patients in remission and identified the critical marker D6S1284 at chromosomal band 6q16. The marker showed a high LOH rate in relapsed patients, whereas for the remission patients the marker was localized in the putative deleted region of only two out of 41 patients.
Furthermore, these data are in line with the data of Foroni et al.
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showing that LOH on chromosome 6q16-q21 correlates with poor prognostic impact in pediatric T-ALL. Yet the findings concerning the prognostic impact of del(6q) contrast with some reports on lymphoid malignancies including pediatric ALL, in which no predictive value of del(6q) for poor outcome was detected. [21] [22] [23] These discrepancies might be explained by our hypothesis that the deletion of a circumscribed region of the q-arm of chromosome 6 is associated with poor outcome, whereas 6q deletions not involving this critical region do not affect outcome. One patient without LOH died at day 2 of induction owing to initial complications (case 58), and one patient with LOH on 6q died owing to treatment-related toxicity 6 months after the start of chemotherapy (case 19). Both patients were excluded from further analyses of the prognostic impact of LOH at chromosome 6q14-q24.
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Several genes involved in cellular signaling or transcription factors are allocated to chromosome 6q16 (GDB http:// www.ncbi.nlm.nih.gov/entrez/query.fcgi?db ¼ Genome). EPHA7, located centromeric to marker D6S1284/D6S1716, was recently shown to be downregulated in colorectal cancer by hypermethylation, providing evidence that the EPHA7 gene is involved in human colorectal carcinogenesis. 49 Interestingly, the transcription factor POU3F2, located closely telomeric to marker D6S1716, is overexpressed in melanoma cells compared to normal melanocytes. 50 Another candidate gene on chromosomal band 6q16 is Cyclin C, which is expressed in lymphoid cells and has been implicated in the negative regulation of cell growth. 51, 52 GRIK2, located 3 Mb telomeric to markers D6S1284/D6S1716, was suggested as a candidate tumor suppressor gene in ALL and is significantly downregulated in T-ALL samples with del(6q). 18 Further studies will be necessary to clarify whether deletion of the critical region of 6q leads to altered expression of any of the above-mentioned genes and identify the mechanism responsible for the altered chemosensitivity of the lymphoma cells. Also worth further investigation is whether epigenetic phenomena might explain the critical effect of 6q deletions on outcome.
The prognosis for patients with T-LBL who fail frontline treatment is still very poor. 53 Therefore, parameters that allow early adaptation of frontline treatment to different relapse risks are urgently needed. Our results might be a first step in identifying specific genetic alterations in T-LBL cells to distinguish low-and high-risk patients, thus enabling risk adaptation of frontline treatment.
Supplementary Information on the primer sequences and the cytogenetic localization of the microsatellite markers is given in Supplementary Table 1, which is available at Leukemia's website. No. of results: the number of patients in whom a result was obtained for the particular microsatellite marker; Informative result: successful fragmentlength analysis of a microsatellite marker of a patient in germline DNA and tumor DNA (results were regarded as informative in case of heterozygous status of germline DNA and retained heterozygosity or LOH in tumor DNA compared with germline DNA); no. of informative results: the number of patients in whom an informative result was obtained for the particular microsatellite marker; No. of LOH: the number of patients in whom LOH was detected for the particular microsatellite marker; Rate of LOH: rate of findings of LOH in the total number of informative results for a distinct microsatellite marker.
Bold characters indicate significant P-values.
